OncLive | Novel B-Cell Receptor Signaling Inhibitors Show Promise OncLive Many of the patients in these studies were heavily pretreated, and many did not achieve objective responses, so the interest is in combining it with other active agents, such as bendamustine and rituximab. Whichever agent is used with idelalisib, the ... |
